clinical trial · NCT05723874
A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
Boehringer Ingelheim·phase1·completed·n = 14
HealthyBI 425809Bosentan
brief summary
The main objective of this trial is to investigate the relative bioavailability of BI 425809 given alone (Reference) compared to a combined administration with the moderate CYP3A4 inducer bosentan (Test) following repeated oral administration.
started
Mar 6, 2023
primary completion
May 26, 2023
completion
May 26, 2023
last updated
Mar 30, 2026
official title
The Effect of Multiple Oral Doses of Bosentan on the Steady State Kinetics of BI 425809 After Oral Administration to Healthy Male Subjects (an Open-label, Two-period Fixed Sequence Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol